Keros Therapeutics, Inc. (KROS)
19.26
-0.27
(-1.38%)
USD |
NASDAQ |
Jan 15, 16:00
19.27
+0.01
(+0.05%)
After-Hours: 20:00
Keros Therapeutics SG&A Expense (TTM): 45.77M for Sept. 30, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Eli Lilly & Co. | 10.39B |
| Pfizer Inc. | 13.91B |
| Innoviva, Inc. | 112.52M |
| Ocugen, Inc. | 27.76M |
| Bionano Genomics, Inc. | 38.19M |